Paclitaxel-Eluting Not Noninferior to Everolimus-Eluting Stent

This article originally appeared here.
Share this content:
Paclitaxel-Eluting Not Noninferior to Everolimus-Eluting Stent
Paclitaxel-Eluting Not Noninferior to Everolimus-Eluting Stent

THURSDAY, Oct. 15, 2015 (HealthDay News) -- Paclitaxel-eluting stents are not noninferior to everolimus-eluting stents for patients with diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention (PCI), according to a study published online Oct. 14 in the New England Journal of Medicine to coincide with the Transcatheter Cardiovascular Therapeutics meeting, held from Oct. 11 to 15 in San Francisco.

Upendra Kaul, M.D., from the Fortis Escorts Heart Institute in India, and colleagues randomized 1,830 patients with diabetes mellitus and coronary artery disease who were undergoing PCI to receive a paclitaxel-eluting stent or an everolimus-eluting stent in a noninferiority trial. The primary end point was target-vessel failure (composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization) at one year follow-up.

The researchers found that compared with the everolimus-eluting stent group, the paclitaxel-eluting stent group did not meet the criterion for noninferiority with respect to the primary end point at one year (2.9 versus 5.6 percent; P = 0.38 for noninferiority). The one-year rates of target-vessel failure, spontaneous myocardial infarction, stent thrombosis, target-vessel revascularization, and target-lesion revascularization were significantly higher in the paclitaxel-eluting versus the everolimus-eluting stent group.

"In patients with diabetes mellitus and coronary artery disease undergoing PCI, paclitaxel-eluting stents were not shown to be noninferior to everolimus-eluting stents, and they resulted in higher rates of target-vessel failure, myocardial infarction, stent thrombosis, and target-vessel revascularization at one year," the authors write.

The study was funded by Boston Scientific.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Zika, West Nile Cases Reported in Alabama

Zika, West Nile Cases Reported in Alabama

State health officials note that Zika hasn't been transmitted locally

TBI Linked to Increased Suicide Risk

TBI Linked to Increased Suicide Risk

Increased suicide risk with one, two, and three or more medical contacts for traumatic brain injury

Triple Combo Blood Pressure Pill Can Improve BP Control

Triple Combo Blood Pressure Pill Can Improve BP ...

Proportion achieving target BP increased with use of triple combo pill versus usual care at six months

is free, fast, and customized just for you!




Already a member?

Sign In Now »